Genetic Basis of Non-Familial IgA Nephropathy
非家族性 IgA 肾病的遗传基础
基本信息
- 批准号:7637963
- 负责人:
- 金额:$ 30.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-06-16 至 2013-05-31
- 项目状态:已结题
- 来源:
- 关键词:7p13AddressAmino AcidsAnabolismAntibodiesAntigensAutoantibodiesAutoimmune DiseasesB-LymphocytesBindingBiological AssayBlood CellsCell LineCell surfaceCellsComplementary DNADepositionDiagnosisEmbryoEnzyme-Linked Immunosorbent AssayEnzymesEvaluationExonsGalactoseGalactosyltransferasesGenesGeneticGlomerulonephritisGlycopeptidesGlycoproteinsGoalsHematopoietic stem cellsHumanIGA GlomerulonephritisIgA1Immunoglobulin AImmunoglobulinsIn VitroInflammationKidney DiseasesKidney FailureLightLinkMammalsMapsMasksMembrane GlycoproteinsMethodsMolecularMolecular ChaperonesMono-SMusMutateMutationO-Glycans Biosynthesis PathwayPathogenesisPathway interactionsPatientsPlasma CellsPolysaccharidesPreventionProteinsRecombinantsSamplingSerumSeveritiesSiteSomatic MutationStructureSyndromeTestingTherapeuticTn antigenTumor Cell LineXq24baseglycosylationin vivoinhibitor/antagonistinsightmulticatalytic endopeptidase complexnovelnovel diagnosticsperipheral bloodpreventpublic health relevancesialosyl-Tn antigen
项目摘要
DESCRIPTION (provided by applicant): Immunoglobulin A (IgA) nephropathy (IgAN) or Berger's disease is an autoimmune disease resulting from the abnormal deposit of IgA in the glomerulus. Primary IgAN is the most common form of primary glomerulonephritis, leading to progressive renal failure in almost one third of the patients. Numerous studies have suggested that IgAN results from abnormal O-glycosylation of IgA1. Normal IgA1 is unique among immunoglobulins in that it contains ~5 Ser/Thr-linked O-glycans with mono-sialylated and di-sialylated core 1 structures. The pathogenesis of the IgAN is associated with a deficiency of galactose in O-glycans and concomitant expression of the Tn antigen (GalNAc?-Ser/Thr) in its hinge region of IgA1. Tn antigen is normally masked through addition of galactose by the T-synthase to generate the core 1 structure (Gal(3GalNAc-R). We discovered that T-synthase requires a unique molecular chaperone we termed Cosmc that helps to fold the T-synthase during its biosynthesis in the ER. Cosmc is encoded on Xq24 and is an ER chaperone that prevents the aggregation/proteasomal degradation of the T-synthase. Preliminary studies show that somatic mutations in Cosmc cause expression of the Tn antigen. We now hypothesize that somatic mutations of Cosmc in IgA-secreting B cells cause undergalactosylation of IgA1 and result in non-familial or sporadic IgAN. In this proposal, we will focus on three Specific Aims. Aim 1: We will analyze Cosmc in Tn/CD19(+) B lymphocytes from peripheral blood of patient with IgAN. For all mutations found, the effects of mutation on Cosmc chaperone toward the T-synthase will be examined by in vitro complementation assays. We will isolate, immortalize and establish the Tn/CD19(+) or Tn/IgA(+) Blymphocytes from patients with IgAN, examine the cDNA and gene for Cosmc; introduce wild type Cosmc into the B cells to restore T-synthase activity; and test whether Cosmc expression corrects O-glycosylation of cell surface glycoproteins and IgA1. Aim 2: We will define the structures of O-glycans on each site of the hinge region in IgA from patients with IgAN. Aim 3: We will characterize the autoantibodies in sera of patients with IgAN using a glycan microarray including various glycans and synthetic glycopeptides representing the IgA1 hinge region, and establish an ELISA method for potential diagnosis of IgAN from serum samples. Understanding the genetic basis for IgAN will shed light on developing new diagnostics and therapeutic treatments for IgAN. PUBLIC HEALTH RELEVANCE Our goal of this project is to investigate the genetic basis or molecular mechanism of non-familial IgA nephropathy (IgAN), the most common form of primary glomerulonephritis leading to progressive renal failure in almost one third of the patients. IgAN is caused by the deposit of IgA1 in glomerulus because the IgA1 carries aberrant O-glycans such as Tn antigen. O-glycan biosynthesis is regulated by Cosmc, core 1 (3-galactosyltransferase specific molecular chaperone, through assisting the folding of core 1 (3- galactosyltrasferase (T-synthase) which is a key enzyme guarding the pathway. Human Cosmc is encoded by a single-Exon gene Cosmc on Xq24. Somatic mutation in Cosmc is responsible for the abnormal expression of Tn and sialylTn antigens in human tumor cell lines and blood cells of patients with Tn syndrome. We hypothesize that the somatic mutation of X-linked Cosmc in IgA1 secreting B cell is associated with IgAN. To test our hypothesis, we will focus on three Aims for this proposal: 1) Examine Cosmc gene in Tn(+), IgA1 secreting B cells or plasma cells isolated from patients with IgAN and matched healthy controls; examine the Cosmc gene from immortalized Tn(+), IgA1 secreting B cells or plasma cells; correct the O-glycan structure on IgA1 by introducing the wild type Cosmc into these cells; 2) Define the O-glycan structure on each site of hinge region in IgA1; 3) Characterize the autoimmune antibody in sera of patients with IgAN. These studies will directly address the molecular mechanism of IgAN, which will have an important impact on our understanding of the pathogenesis of IgA1, and provide new diagnostics and avenues of treatment or prevention for sporadic IgAN.
描述(由申请人提供):免疫球蛋白A(伊加)肾病(IgAN)或伯杰病是一种自身免疫性疾病,由肾小球中伊加的异常存款引起。原发性IgAN是原发性肾小球肾炎最常见的形式,导致几乎三分之一的患者发生进行性肾衰竭。许多研究表明IgAN是由IgA 1的异常O-糖基化引起的。正常IgA 1在免疫球蛋白中是独特的,因为它含有~5个Ser/Thr连接的O-聚糖,具有单唾液酸化和二唾液酸化的核心1结构。IgAN的发病机制与O-聚糖中半乳糖的缺乏和伴随的Tn抗原(GalNAc?Ser/Thr)。Tn抗原通常通过由T-合酶添加半乳糖以产生核心1结构(Gal(3GalNAc-R))来掩蔽。我们发现,T-合酶需要一个独特的分子伴侣,我们称之为Cosmc,有助于折叠T-合酶在ER的生物合成过程中。Cosmc在Xq 24上编码,是一种ER分子伴侣,可防止T合酶的聚集/蛋白酶体降解。初步研究表明,Cosmc的体细胞突变导致Tn抗原的表达。我们现在假设IgA分泌B细胞中Cosmc的体细胞突变导致IgA 1半乳糖基化不足,并导致非家族性或散发性IgA肾病。在这份提案中,我们将重点关注三个具体目标。目的1:分析IgA肾病患者外周血Tn/CD 19(+)B淋巴细胞中Cosmc的表达。对于发现的所有突变,将通过体外互补测定来检查突变对Cosmc分子伴侣对T-合酶的影响。我们将从IgAN患者中分离、永生化并建立Tn/CD 19(+)或Tn/伊加(+)B淋巴细胞,检测Cosmc的cDNA和基因;将野生型Cosmc导入B细胞以恢复T-合酶活性;并检测Cosmc表达是否纠正细胞表面糖蛋白和IgA 1的O-糖基化。目的2:我们将确定的结构上的铰链区在IgA患者伊加的每个网站上的O-聚糖。目标三:我们将使用包括各种聚糖和代表IgA 1铰链区的合成糖肽的聚糖微阵列来表征IgAN患者血清中的自身抗体,并建立用于从血清样品中潜在诊断IgAN的ELISA方法。了解IgAN的遗传基础将有助于开发IgAN的新诊断和治疗方法。 本项目的目的是研究非家族性伊加肾病(IgAN)的遗传基础或分子机制,IgAN是原发性肾小球肾炎中最常见的形式,导致近三分之一的患者发生进行性肾衰竭。IgA肾病是由IgA 1在肾小球中的存款引起的,因为IgA 1携带异常的O-聚糖,如Tn抗原。O-聚糖生物合成受Cosmc(核心1 β-半乳糖基转移酶特异性分子伴侣)的调控,Cosmc通过辅助核心1 β-半乳糖基转移酶(T-合成酶)的折叠来调节,核心1 β-半乳糖基转移酶是O-聚糖生物合成途径的关键酶。人Cosmc基因由Xq 24上的单外显子基因Cosmc编码。Cosmc的体细胞突变导致Tn和sialylTn抗原在人肿瘤细胞系和Tn综合征患者血细胞中的异常表达。我们推测IgA 1分泌型B细胞中X连锁Cosmc的体细胞突变与IgA肾病有关。为了验证我们的假设,我们将集中在三个方面:1)检测从IgAN患者和匹配的健康对照中分离的Tn(+)、分泌IgA 1的B细胞或浆细胞中的Cosmc基因;检测从永生化的Tn(+)、分泌IgA 1的B细胞或浆细胞中的Cosmc基因; 2)确定IgA 1铰链区各位点的O-聚糖结构; 3)鉴定IgAN患者血清中的自身免疫抗体。这些研究将直接解决IgAN的分子机制,这将对我们理解IgA 1的发病机制产生重要影响,并为散发性IgAN提供新的诊断和治疗或预防途径。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tongzhong Ju其他文献
Tongzhong Ju的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tongzhong Ju', 18)}}的其他基金
Novel Technologies for Quantitative O-glycomics and Amplification/Preparation of Cellular O-Glycans
定量 O-糖组学和细胞 O-聚糖扩增/制备的新技术
- 批准号:
9167145 - 财政年份:2016
- 资助金额:
$ 30.6万 - 项目类别:
Genetic Basis of Non-Familial IgA Nephropathy
非家族性 IgA 肾病的遗传基础
- 批准号:
7812064 - 财政年份:2008
- 资助金额:
$ 30.6万 - 项目类别:
Genetic Basis of Non-Familial IgA Nephropathy
非家族性 IgA 肾病的遗传基础
- 批准号:
8088062 - 财政年份:2008
- 资助金额:
$ 30.6万 - 项目类别:
Genetic Basis of Non-Familial IgA Nephropathy
非家族性 IgA 肾病的遗传基础
- 批准号:
8279409 - 财政年份:2008
- 资助金额:
$ 30.6万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 30.6万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 30.6万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 30.6万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 30.6万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 30.6万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 30.6万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 30.6万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 30.6万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 30.6万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 30.6万 - 项目类别:
Research Grant














{{item.name}}会员




